Recently, Brise Pharmaceuticals Co. Ltd. (Brise), a clinical-stage, pioneering company specializing in innovative treatments for acute and chronic pain, announced that Dr. Danny Chen has joined the company as Research and Development President of the group company，leading the pre-clinical and clinical research activities. His responsibilities will include strengthening Brise's overall R&D capabilities and accelerating the development of Brise’s pipeline. At the same time, Dr. Chen is appointed as Chief Executive Officer (CEO) of the US subsidiary, overseeing the establishment and operation of the US subsidiary, aiming to enhance the company's global R&D and business development capabilities.
Dr. Chen has more than 20 years of research and management experience in the pharmaceutical industry. He has a deep and comprehensive understanding of the entire drug development process, from target discovery and validation to candidate selection, preclinical and clinical development, and drug registration. With a track record of over 30 IND/CTA applications, he has led multiple global clinical programs and secured NDA approvals. His expertise spans neuroscience, metabolism, and immunology, with a particular focus on pain and chronic disease drug development.
Most recently, Dr. Chen served as Senior Vice President, Chief Scientist of Non-Oncology R&D and Head of Beijing Innovation Center at Simcere Pharmaceutical Group, where he was responsible for advancing the company's translational science, building the neuroscience research center in Beijing, and transforming the non-oncology pipeline. Previously, Dr. Chen served Senior Vice President, Head of Translation Medicine at SciNeuro Pharmaceuticals, overseeing non-clinical development and translational medicine activities. Prior to SciNeuro, Dr. Chen served as Executive Director, Clinical Pharmacology Group Head ofCNS and Internal Medicine Research Unit Head at Pfizer(US). Dr. Chen earned his Ph.D. in Pharmaceutical Science from the Ohio State University.
